SGSilpa Gampala

Silpa Gampala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Silpa Gampala has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Post-Translational Modification (PTM) Proteomics Reveals Early Redox and Mitochondrial Remodeling Following Ref-1 Inhibition in Pancreatic Cancer

    by Silpa Gampala, Xiaolu Li, Jesse B. Trejo, Marina A. Gritsenko, Rosalie Chu, Wei-Jun Qian, Elizabeth Sierra Potchanant, Melissa L. Fishel, Tong Zhang, Mark R. Kelley

    Apurinic/apyrimidinic endonuclease 1/redox factor-1 (Ref-1/APE1) is a central regulator of redox-dependent transcriptional signaling that promotes pancreatic ductal adenocarcinoma (PDAC) progression, therapeutic resistance, and metabolic adaptation. While pharmacologic inhibition of Ref-1 suppresses tumor growth and alters cellular metabolism, immediate molecular events linking Ref-1 inhibition to downstream cellular adaptation remain poorly understood. We applied an integrated multiplexed proteomics workflow to simultaneously quantify global protein abundance, cysteine oxidation, phosphorylation, and lysine acetylation in Pa03C PDAC cells following acute treatment (30–120 min) with the second-generation Ref-1 redox inhibitor APX2014. APX2014 induced extensive remodeling of the PTM landscape across multiple regulatory layers in PDAC while producing minimal changes in global protein abundance. Cysteine oxidation represented the earliest and most sustained response, accompanied by widespread phosphorylation and delayed lysine acetylation. Integrated pathway analyses identified mitochondrial translation, respiratory electron transport, TCA cycle metabolism, and mitochondrial redox homeostasis as early, consistently regulated processes. Functional mitochondrial assays confirmed impaired utilization of TCA cycle substrates following APX2014 treatment. Coordinated PTM remodeling was observed on Ref-1-associated signaling proteins, including NF-κB1 and p53, revealing simultaneous regulation of oxidation, phosphorylation, and acetylation within functionally important domains. Early redox-sensitive protein networks were associated with subsequent disruption of mitotic organization. Together, these findings demonstrate that pharmacologic Ref-1 redox inhibition rapidly rewires regulatory signaling networks before detectable changes in protein abundance and identify mitochondrial redox remodeling as an early consequence of Ref-1 inhibition, providing systems-level insight into how Ref-1-targeted therapies disrupt metabolic and stress-adaptive programs in pancreatic cancer. This work establishes a framework for understanding Ref-1-directed therapeutics and highlights integrated PTM profiling for defining early drug response mechanisms. These findings provide a translational rationale for advancing next-generation Ref-1 redox inhibitors such as APX2014, developed from the first-in-class inhibitor APX3330 currently in clinical trials, and underscore the therapeutic potential of targeting Ref-1 redox signaling in pancreatic cancer.

  • Open Access

    Integrated Post-Translational Modification (PTM) Proteomics Reveals Early Redox and Mitochondrial Remodeling Following Ref-1 Inhibition in Pancreatic Cancer

    by Silpa Gampala, Xiaolu Li, Jesse B Trejo, Marina A Gritsenko, Rosalie K Chu, Wei-Jun Qian, Elizabeth Sierra Potchanant, Melissa Fishel, Tong Zhang, Mark Kelley

    Background: Apurinic/apyrimidinic endonuclease 1/redox factor-1 (Ref-1/APE1) is a central regulator of redox-dependent transcriptional signaling that promotes pancreatic ductal adenocarcinoma (PDAC) progression, therapeutic resistance, and metabolic adaptation. While pharmacologic inhibition of Ref-1 suppresses tumor growth and alters cellular metabolism, immediate molecular events linking Ref-1 inhibition to downstream cellular adaptation remain poorly understood. We therefore sought to characterize proteome-wide signaling responses induced by second-generation Ref-1 redox inhibitor, APX2014. Methods: We applied an integrated multiplexed proteomics workflow to simultaneously quantify global protein abundance together with cysteine oxidation, phosphorylation, and lysine acetylation in Pa03C PDAC cells following acute treatment (30-120 min) with selective Ref-1 redox inhibitor APX2014. Differential post-translational modification (PTM) analysis, pathway enrichment, structural mapping of regulated sites, and functional mitochondrial substrate utilization assays were performed to define early signaling responses. Results: APX2014 induced rapid and extensive remodeling of PTM landscape while producing minimal changes in global protein abundance. Cysteine oxidation represented the earliest and most sustained response, accompanied by widespread phosphorylation and delayed lysine acetylation. Integrated pathway analyses identified mitochondrial translation, respiratory electron transport, TCA cycle metabolism, and mitochondrial redox homeostasis as the earliest and most consistently regulated processes. Functional mitochondrial assays confirmed impaired utilization of TCA cycle substrates following APX2014 treatment. Coordinated PTM remodeling was observed on Ref-1-associated signaling proteins, including NFkB1 and p53, revealing simultaneous regulation of oxidation, phosphorylation, and acetylation within functionally important domains. Early redox-sensitive protein networks were also associated with subsequent disruption of mitotic organization. Conclusions: Integrated multi-PTM proteomics reveals that pharmacologic Ref-1 redox inhibition rapidly rewires regulatory signaling networks before detectable changes in protein abundance. Our findings identify mitochondrial redox remodeling as an early consequence of Ref-1 inhibition, providing systems-level insight into how Ref-1-targeted therapies disrupt metabolic and stress-adaptive programs in pancreatic cancer. This work establishes a framework for understanding the molecular basis of Ref-1-directed therapeutics and highlights integrated PTM profiling as a powerful strategy for defining early drug response mechanisms. These findings provide a strong translational rationale for advancing next-generation Ref-1 redox inhibitors such as APX2014, developed from the first-in-class inhibitor APX3330 currently in clinical trials, and underscore the broader therapeutic potential of targeting Ref-1 redox signaling in pancreatic cancer.

  • Open Access

    PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors

    by Dingxun Wang, Melissa L. Fishel, Azadeh Samiei, Silpa Gampala, Changdeng Hu, Shaoxiong Chen, GuangJun Zhang

    Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive sarcomas with poor prognosis and a strong tendency for metastasis and relapse. Surgical removal remains the mainstay of treatment but is frequently ineffective or impractical. Currently, no effective targeted therapy exists for this type of malignancy. PRMT5 has recently emerged as a promising therapeutic target in various human cancers with MTAP loss, which results in cancer cell dependency on PRMT5 activity. The frequent loss of MTAP in MPNSTs suggests that PRMT5 inhibition is a promising therapeutic option and enables the stratification of cancer patients with few treatment options. We first examined human nerve sheath tumor samples and found that increased PRMT5 expression and activity correlated with MTAP loss in 86.8% (33/38) of MPNSTs and in atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP) (5/5). When PRMT5 activity was inhibited genetically and chemically, the cell growth of MTAP-deficient MPNST cell lines was suppressed, but not that of MTAP-proficient MPNST cell lines. Moreover, in the PRMT5-inhibited MTAP-deficient MPNST cell lines, spontaneous DNA damage accumulation was observed following G2/M cell cycle arrest. The DNA replication stress marker RPA32 decreased, and CHK1 was activated early after PRMT5 knockdown, likely contributing to the accumulation of DNA damage. Additionally, we combined PRMT5 inhibition with the DNA-damaging agents doxorubicin and gemcitabine, resulting in synergistic effects and increased cancer cell death in MTAP-deficient MPNST cell lines. Together, these findings identify PRMT5 as a compelling therapeutic target in MTAP-deficient MPNSTs. This PRMT5 inhibition strategy has strong translational potential for MPNSTs.

  • Open Access

    ZNF423 depletion induces the integrated stress response and represents a potential vulnerability in NF1-associated MPNST

    by Sarah K. Morrow, Christine A. Berryhill, Emily E. White, Colin J. Beach, Shelley A. H. Dixon, Emily Y. Zhang, Christopher Davis, Erin M. Mannion, Brooke E. Hickey, Henry Mang, et al.

    Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with limited systemic therapies and represent the leading cause of mortality for individuals with neurofibromatosis type 1 (NF1). Malignant progression can reactivate developmental precursor programs that are largely absent from normal nerve and benign tumors, creating tumor-selective vulnerabilities. Zinc finger protein 423 (ZNF423; also known as OAZ/ROAZ) is a developmentally regulated transcription factor that delays olfactory precursor differentiation and has been implicated in B-cell malignancy. Here, we asked whether ZNF423 is reactivated and functionally required in NF1-associated MPNST. In genetically defined models, Nf1 loss reduced Zfp423 in a benign tumor cell-of-origin context, whereas combined Nf1 and Cdkn2a loss induced marked Zfp423 upregulation during transformation. ZNF423 depletion impaired DNA synthesis and proliferation, induced DNA damage signaling, and activated the integrated stress response (ISR), increasing sensitivity to cytotoxic agents. In an orthotopic MPNST model, shRNA-mediated suppression of ZNF423 reduced tumor initiation in vivo; however, tumors that eventually emerged showed restoration of ZNF423 expression. ZNF423 is developmentally restricted in the peripheral nerve lineage yet elevated in MPNST, with single-cell analyses of patient nerve sheath tumors revealing localized expression restricted to malignant cells rather than SOX10-positive benign tumor cells. These data identify ZNF423 as a putative malignant biomarker, a potential dependency in NF1-MPNST, and nominate downstream stress and genome maintenance pathways as cooperative therapeutic vulnerabilities. STATEMENT OF SIGNIFICANCE: ZNF423 is a developmentally restricted transcription factor selectively reactivated in NF1-associated malignant peripheral nerve sheath tumors. Targeted ablation triggers the integrated stress response, impairs DNA synthesis, sensitizes cells to chemotherapy and PARP inhibition, and restricts in vivo growth. ZNF423 represents a candidate biomarker and therapeutic vulnerability in this aggressive sarcoma.

  • Open Access

    Supplementary Table S19 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

    GOBP spatially profiled ANNUBP downregulated genes

  • Open Access

    Supplementary Figure S2 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

  • Open Access

    Supplementary Table S10 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

    Upregulated protein coding genes from the GSE178989 dataset

  • Open Access

    Supplementary Figure S1 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

    Sciatic Nerve Atlas DLK1 Analysis

  • Open Access

    Supplementary Table S15 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

    TCGA GOBP 2023 Downregulated genes

  • Open Access

    Supplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures

    by Dana K. Mitchell, Kylee Brewster, Stavriani C. Makri, Jaffar Khan, Eric A. Albright, Andrew Horvai, Henry Mang, Qingbo Lu, Shelley A.H. Dixon, Emily White, et al.

    Supplementary Table S12 from DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures